11h
Avacta Reports 11.4-Month Median Progression-Free Survival in Salivary Gland Cancer Trial of AVA6000
Avacta Therapeutics (LSE:AVCT) has reported updated Phase 1a/1b clinical trial results for faridoxorubicin (AVA6000), showing median progression-free survival (PFS) of 11. 4 months in a selected group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results